多肽探针在肿瘤成像中的研究进展

doi:10.11904/j.issn.1002-3070.2022.04.013

Abstract

Abstract: Accurate imaging of tumors plays an important role in identifying tumor location and staging,and determining the appropriate treatment methods.Peptides are promising tools in imaging,and the corresponding receptors have been shown to be overexpressed in tumor cells,leading to imaging agents within tumor cells by specifically binding to the receptors.In addition,peptides have attracted more and more attention in tumor diagnosis and treatment due to their small molecular weight,low immunogenicity,high affinity and specificity,and some peptide-based imaging probes and therapeutic agents have successfully entered clinical trials.This article reviews the research progress of peptide probes in tumor imaging.

Key words: Peptides probe, Tumor, Imaging diagnosis

CLC Number:

R730

GUO Ling, SU Yajuan. Research progress of peptide probe in tumor imaging[J]. Journal of Practical Oncology, 2022, 36(4): 360-363.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.04.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I4/360

References

1 Fan X,Xu H,Song J,et al.Using a membrane-penetrating-peptide to anchor ligands in the liposome membrane facilitates targeted drug delivery[J].Bioconjug Chem,2020,31(1):113-122.
2 黎玉娇,尚乃舰.影像学评估乳腺癌新辅助化疗反应的研究进展[J].实用肿瘤学杂志,2018,153(1):63-67.
3 Hossein-Nejad-Ariani H,Althagafi E,Kaur K,et al.Small peptide ligands for targeting EGFR in triple negative breast cancer cells[J].Sci Rep,2019,9(1):2723.
4 Flatmark K,Torgunrud A,Fleten KG,et al.Peptide vaccine targeting mutated GNAS:a potential novel treatment for pseudomyxoma peritonei[J].J Immunother Cancer,2021,9(10):3109.
5 Vadevoo SMP,Gurung S,Khan F,et al.Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy[J].Arch Pharm Res,2019,42(2):150-158.
6 Zhao N,Qin Y,Liu H,et al.Tumor-Targeting Peptides:ligands for molecular imaging and therapy[J].Anticancer Agents Med Chem,2018,18(1):74-86.
7 Wang W,Hu Z.Targeting Peptide-based probes for molecular imaging and diagnosis[J].Adv Mater,2019,31(45):1804827.
8 Cardle II,Jensen MC,Pun SH,et al.Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targeting[J].J Biol Chem,2021,296:100657.
9 Ramezanizadeh M,Masterifarahani A,Sadeghzadeh N,et al.99mTc-D(RGD):molecular imaging probe for diagnosis of αvβ3-positive tumors[J].Nucl Med Commun,2020,41(2):104-109.
10 Zhang Y,Wang L,Yu S,et al.Synthesis and preclinical evaluation of the fibrin-binding cyclic peptide ¹⁸F-iCREKA:comparison with its contrasted linear peptide[J].Contrast Media Mol Imaging,2019,2019:6315954.
11 Liolios C,Sachpekidis C,Kolocouris A,et al.PET Diagnostic molecules utilizing multimeric cyclic RGD peptide analogs for imaging integrin αvβ3 receptors[J].Molecules,2021,26(6):1792.
12 Xiong J,Yan L,Zou C,et al.Integrins regulate stemness in solid tumor:an emerging therapeutic target[J].J Hematol Oncol,2021,14(1):177.
13 Karamzade-Ziarati N,Manafi-Farid R,Ataeinia B,et al.Molecular imaging of bone metastases using tumor-targeted tracers[J].Q J Nucl Med Mol Imaging,2019,63(2):136-149.
14 Beer AJ,Haubner R,Goebel M,et al.Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer ¹⁸F-galacto-RGD in cancer patients[J].J Nucl Med,2005,46(8):1333-1341.
15 Beer AJ,Niemeyer M,Carlsen J,et al.Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by ¹⁸F-Galacto-RGD PET[J].J Nucl Med,2008,49(2):255-259.
16 Beer AJ,Lorenzen S,Metz S,et al.Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients:a PET study using ¹⁸F-galacto-RGD and ¹⁸F-FDG[J].J Nucl Med,2008,49(1):22-29.
17 Florea A,Mottaghy FM,Bauwens M.Molecular imaging of angiogenesis in oncology:current preclinical and clinical status[J].Int J Mol Sci,2021,22(11):5544.
18 Minamimoto R,Jamali M,Barkhodari A,et al.Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients:an atlas of SUV measurements[J].Eur J Nucl Med Mol Imaging,2015,42(12):1850-1858.
19 Iagaru A,Mosci C,Shen B,et al.(18)F-FPPRGD2 PET/CT:pilot phase evaluation of breast cancer patients[J].Radiology,2014,273(2):549-559.
20 Liu Y,Xu C,Liu HW,et al.Precipitated fluorophore-based molecular probe for in situ imaging of aminopeptidase N in living cells and tumors[J].Anal Chem,2021,93(16):6463-6471.
21 Kis A,Dénes N,Szabó JP,et al.In vivo assessment of aminopeptidase N(APN/CD13)specificity of different ⁶⁸Ga-labelled NGR derivatives using PET/MRI imaging[J].Int J Pharm,2020,589:119881.
22 Israel I,Elflein K,Schirbel A,et al.A comparison of the monomeric[⁶⁸Ga]NODAGA-NGR and dimeric[⁶⁸Ga]NOTA-(NGR)2 as aminopeptidase N ligand for positron emission tomography imaging in tumor-bearing mice[J].Eur J Pharm Sci,2021,166:105964.
23 Yang Y,Zhang J,Zou H,et al.Synthesis and evaluation of ⁶⁸Ga-labeled dimeric cNGR peptide for PET imaging of CD13 expression with ovarian cancer xenograft[J].J Cancer,2021,12(1):244-252.
24 Zhu L,Ding Z,Li X,et al.Research progress of radiolabeled Asn-Gly-Arg(NGR)peptides for Imaging and therapy[J].Mol Imaging,2020,19:1536012120934957.
25 Baratto L,Duan H,Mäcke H,et al.Imaging the distribution of gastrin-releasing peptide receptors in cancer[J].J Nucl Med,2020,61(6):792-798.
26 Touijer KA,Michaud L,Alvarez HAV,et al.Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer[J].Eur Urol Oncol,2019,2(2):166-173.
27 Wieser G,Popp I,Christian Rischke H,et al.Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist ⁶⁸Ga-RM2:Preliminary results in patients with negative or inconclusive [18F] Fluoroethylcholine-PET/CT[J].Eur J Nucl Med Mol Imaging,2017,44(9):1463-1472.
28 Minamimoto R,Hancock S,Schneider B,et al.Pilot comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer[J].J Nucl Med,2016,57(4):557-562.
29 He K,Chi C,Li D,et al.Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery[J].Bioeng Transl Med,2020,6(1):10182.
30 Hu Y,Ye Z,Wang F,et al.Role of somatostatin receptor in pancreatic neuroendocrine tumor development,diagnosis,and therapy[J].Front Endocrinol(Lausanne),2021,12:679000.
31 Zhang L,Vines DC,Scollard DA,et al.Correlation of somatostatin receptor-2 expression with Gallium-68-DOTA-TATE Uptake in neuroblastoma xenograft models[J].Contrast Media Mol Imaging,2017,2017:9481276.
32 Sadowski SM,Neychev V,Millo C,et al.Prospective study of ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites[J].J Clin Oncol,2016,34(6):588-596.
33 Xie Q,Liu T,Ding J,et al.Synthesis,preclinical evaluation,and a pilot clinical imaging study of [18F] AlF-NOTA-JR11 for neuroendocrine neoplasms compared with[⁶⁸Ga]Ga-DOTA-TATE[J].Eur J Nucl Med Mol Imaging,2021,48(10):3129-3140.

[1]	SUN Weiling, ZHANG Minghui, WU Huaxing, ZHAO Yanbin. Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 316-322.
[2]	SUN Fusheng, XU Ye, ZHANG Yongjian, LOU Ge. Research progress and new treatment strategies of ovarian cancer organoids [J]. Journal of Practical Oncology, 2022, 36(4): 346-350.
[3]	LI Yuan, ZHANG Ling. Research progress of mitotic catastrophe in digestive system tumors [J]. Journal of Practical Oncology, 2022, 36(4): 356-359.
[4]	ZHAO Zinan, WANG Guonian. Research progress of SOX4 in digestive system malignant tumors [J]. Journal of Practical Oncology, 2022, 36(4): 364-368.
[5]	YU Xiaolan, LIU Yan, LIU Jiaren. Research progress in the inhibitory effects of plant anthocyanins on tumors [J]. Journal of Practical Oncology, 2022, 36(3): 245-249.
[6]	LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment [J]. Journal of Practical Oncology, 2022, 36(3): 250-254.
[7]	YANG Nan, WANG Zhao, ZHANG Yu, ZHANG Yunyan. Research progress of SMYD2 in malignant tumors [J]. Journal of Practical Oncology, 2022, 36(3): 273-277.
[8]	WANG Leilei, CHEN Hui. Progress in the treatment of T1 high-grade urothelial carcinoma [J]. Journal of Practical Oncology, 2022, 36(3): 283-287.
[9]	ZHANG Ning, LIN Liuya, LI Sifan, ZHU Meng. Effects of miR-106a targeting TIMP2 on proliferation,metastasis and EMT of human gastric cancer [J]. Journal of Practical Oncology, 2022, 36(2): 105-110.
[10]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[11]	LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(2): 167-172.
[12]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[13]	WANG Yanping, QIU Lin, WU Meng, SA Rina. Analysis of the incidence and mortality of malignant tumors in Shaanxi province in 2016 [J]. Journal of Practical Oncology, 2022, 36(1): 1-6.
[14]	DONG Lina, LIANG Tian, ZHANG Xian, ZHANG Guangmei. Research progress on tropism of ovarian cancer to fat-rich omentum organs [J]. Journal of Practical Oncology, 2022, 36(1): 54-58.
[15]	SHI Jingtong, CHEN Minjie, SUN Yihua. Research progress in the role of malignant tumor-derived exosomes in the M2 polarization of macrophages [J]. Journal of Practical Oncology, 2022, 36(1): 59-63.

Research progress of peptide probe in tumor imaging

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments